# Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

> **NCT06716814** · PHASE3 · RECRUITING · sponsor: **Swedish Orphan Biovitrum** · enrollment: 104 (estimated)

## Conditions studied

- Haemophilia A (Moderate or Severe)

## Interventions

- **DRUG:** Efanesoctocog alfa

## Key facts

- **NCT ID:** NCT06716814
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716814, "Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06716814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*